

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6635642

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
EXELA PHARMA SCIENCES, LLC	03/30/2021
RECEIVING PARTY DATA	
Name:	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
Street Address:	780 THIRD AVENUE, 37TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10017
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17164263
Application Number:	17188922
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7043778156
Email:	jcarusone@robinsonbradshaw.com
Correspondent Name:	JENNIFER CARUSONE
Address Line 1:	101 N. TRYON ST. SUITE 1900
Address Line 2:	C/O ROBINSON, BRADSHAW & HINSON, P.A.
Address Line 4:	CHARLOTTE, NORTH CAROLINA 28246
ATTORNEY DOCKET NUMBER:	20046.00114
NAME OF SUBMITTER:	JENNIFER CARUSONE
SIGNATURE:	/Jennifer Carusone/
DATE SIGNED:	04/01/2021
Total Attachments: 3	
source=Deerfield - Exela - IP Security Agreement (Exela Pharma Sciences) Third Amendment - EXECUTED#page1.tif	
source=Deerfield - Exela - IP Security Agreement (Exela Pharma Sciences) Third Amendment - EXECUTED#page2.tif	

**THIRD AMENDMENT TO
GRANT OF SECURITY INTEREST
IN PATENTS AND TRADEMARKS**

March 30, 2021

WHEREAS, EXELA PHARMA SCIENCES, LLC (the “Pledgor”) previously executed and delivered a Pledge and Security Agreement (as amended, modified, restated or supplemented from time to time, the “Security Agreement”), dated as of April 19, 2017 and a Grant of Security Interest in Patents and Trademarks dated as of April 19, 2017 (the “Original IP Security Agreement”) and amended on September 27, 2019 and June 30, 2020, in favor of Deerfield Private Design Fund IV, L.P., as Collateral Agent (the “Collateral Agent”), with offices at 780 Third Avenue, 37th Floor, New York, New York 10017;

WHEREAS, the Pledgor has acquired additional Trademarks and Patents (as such terms are defined in the Original IP Security Agreement) and desires to hereby confirm the pledge of, and the grant of a security interest in, such additional Trademarks and Patents in favor of the Collateral Agent.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as security for the payment and performance of the Secured Obligations (as defined in the Security Agreement), the Pledgor does hereby grant to the Collateral Agent a security interest in all of its right, title and interest in and to the additional Trademarks and the Patents listed on Schedule A hereto, and the use thereof, together with all proceeds and products thereof and the goodwill of the businesses symbolized by the Trademarks. This Grant has been given in conjunction with the security interest granted to the Collateral Agent under the Security Agreement, and the provisions of this Grant are without prejudice to and in addition to the provisions of the Security Agreement, which are incorporated herein by this reference.

IN WITNESS WHEREOF, the Pledgor has caused this Third Amendment to Grant of Security Interest in Patents and Trademarks to be executed under seal by their duly authorized officers as of the date first above written.

EXELA PHARMA SCIENCES, LLC, a Pledgor

By: Exela PharmSci, Inc., its sole member

Phanesh
Koneru

Digitally signed by
Phanesh Koneru
Date: 2021.03.29
16:11:01 -04'00'

By:

Name: Phanesh B. Koneru

Title: President, Chief Executive Officer and Secretary

SCHEDULE A

TRADEMARKS AND TRADEMARK APPLICATIONS

None.

PATENTS AND PATENT APPLICATIONS

<u>Owner</u>	<u>Title</u>	<u>Application / Registration No.</u>	<u>Inventor</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>
Exela Pharma Sciences, LLC	Stable, highly pure L- cysteine compositions for injection and methods of use	17/164,263	John Maloney; Aruna Koganti; Phanesh Koneru;	USA	2/1/2021	Pending
Exela Pharma Sciences, LLC	Stable, highly pure L- cysteine compositions for injection and methods of use	17/188,922	John Maloney; Aruna Koganti; Phanesh Koneru;	USA	3/1/2021	Pending